Hints and tips:
Related Special Reports
Related Topics
...In October 2019, Merck also completed a €5.8bn acquisition of US-based Versum Materials, which makes critical components used in semiconductors. Merck declined to comment....
...Merck has upped its profit and revenue guidance for this year as sales of its blockbuster cancer treatment Keytruda continue to surge....
...The news mark another disappointment for Merck, which two years ago halted work on a cancer drug that had also been hailed as a potential blockbuster....
...Merck estimates that 2.8mn people have MS, a neurological condition with symptoms including balance and movement problems, pain and tiredness....
...Merck KGaA chief Belén Garijo will be all too aware of the highs and sudden crushing lows of drug trials....
...Merck cut its full year earnings outlook because of a charge related to its $22bn partnership deal with Japanese group Daiichi Sankyo, as the US pharma group invests in cancer drugs....
...Merck Mercuriadis, adviser to Hipgnosis Songs Fund, has offered to drop a controversial clause giving him the right to buy the group’s music portfolio as he battles to stay on at the investment trust he...
...Merck said it will record a pretax charge of $5.5bn as a result of the deal....
...Other earnings: Merck, Caterpillar, Honeywell, Bristol Myers Squibb, Altria, Northrop Grumman, Royal Caribbean Cruises, Southwest Airlines, American Airlines, Harley-Davidson and Hertz are reporting before...
...Dean Li, president of Merck’s research laboratories, praised the UK’s scientific talent and expertise, hoping that the investment in King’s Cross will help researchers at MSD, known as Merck in the US, work...
...Merck knows how that feels. Its shares slumped 12 per cent on Wednesday after a multiple sclerosis medicine flopped in late-stage trials....
...Hipgnosis was founded by music executive Merck Mercuriadis in 2018 to turn music rights into a mainstream asset class....
...Merck raised its full year revenue forecasts to between $58.6bn and $59.6bn, up from an earlier forecast of $57.7bn and $58.9bn....
...Founded by Merck Mercuriadis in 2018, Hipgnosis was at the forefront of attempts to transform music rights into a mainstream asset class as investors sought higher returns during the era of low interest...
...Opdivo actually outperformed Keytruda in product sales from 2014 to 2017, at which point Merck’s lifecycle efforts paid off, and it has since been far more successful....
...Big share price moves in Europe on Wednesday include German tour operator Tui, German pharmaceutical company Merck, and London-listed British American Tobacco: Tui: Shares in the tour operator surged 6.3...
...Investment adviser and music mogul Merck Mercuriadis was a frontman as crowd-pleasing as any stadium rocker The net asset value rose from a few hundred million dollars to $2.2bn at the end of last year....
...New data from Moderna and Merck this week offered a promising update on this front....
...And it violates the constitution in at least two obvious respects,” said Merck in a court filing....
...Merck will pay the Chinese company €160mn upfront as part of the deal. Broker Jeffries cut its target price for Merck to €173 from €201....
...And what are the incentives of Merck Mercuriadis after the transaction?...
...By October, JSR’s board had considered and rejected Merck’s proposal, arguing that there was insufficient synergy....
...The deal comes as pharmaceutical companies gather in San Francisco for an annual industry conference, with GSK rivals Johnson & Johnson, Novartis and Merck announcing acquisitions on Monday....
...Hipgnosis was founded by music executive Merck Mercuriadis in 2018 to turn music rights into a mainstream asset class, using the rising royalties from streaming, radio play and performances to provide income...
...HSF was founded by music executive Merck Mercuriadis in 2018 to turn music rights into an asset class. He was HSM’s chief executive until February, when he became its chair....
International Edition